
Opinion|Videos|December 19, 2024
Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases
Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Anti-VEGF treatments have been available for age-related macular degeneration and diabetic macular edema for over a decade. Can you discuss how they have impacted patient outcomes and what barriers remain to achieving optimal results?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Dry AMD — Geographic atrophy, photobiomodulation, and the road ahead
2
Retina World Congress 2026: The dopamine-AMD connection
3
Retina World Congress 2026: Port Delivery System shows durable outcomes at 7 years in neovascular AMD
4
Retina World Congress 2026: Expanding the DME treatment algorithm beyond anti-VEGF
5





















